Characterization of two affinity matured Anti-Yersinia pestis F1 human antibodies with medical countermeasure potential
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0305034 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Nileena Velappan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Biosciences Division, Los Alamos National Laboratory, Los Alamos, NM, United States of America. Hauptthemen laut MEDLINE: Yersinia pestis, Plague, Antibodies, Bacterial. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Los Alamos National Laboratory.
Abstract (Originalsprache)
Yersinia pestis , the causative agent of plague and a biological threat agent, presents an urgent need for novel medical countermeasures due to documented cases of naturally acquired antibiotic resistance and potential person-to-person spread during a pneumonic infection. Immunotherapy has been proposed as a way to circumvent current and future antibiotic resistance. Here, we describe the development and characterization of two affinity matured human antibodies (αF1Ig AM2 and αF1Ig AM8) that promote survival of mice after exposure to aerosolized Y . pestis . We share details of the error prone PCR and yeast display technology-based affinity maturation process that we used. The resultant matured antibodies have nanomolar affinity for Y . pestis F1 antigen, are produced in high yield, and are resilient to 37°C stress for up to 6 months. Importantly, in vitro assays using a murine macrophage cell line demonstrated that αF1Ig AM2 and αF1Ig AM8 are opsonic. Even more importantly, in vivo studies using pneumonic plague mouse models showed that 100% of the mice receiving 500 μg of IgGs αF1Ig AM2 and αF1Ig AM8 survived lethal challenge with aerosolized Y . pestis CO92. Combined, these results provide evidence of the quality and robustness of αF1Ig AM2 and αF1Ig AM8 and support their development as potential medical countermeasures against plague.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Biosciences Division, Los Alamos National Laboratory, Los Alamos, NM, United States of America.
- Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD, United States of America.
- Biostatisitics Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD, United States of America.
- Carterra, Walnut Creek, CA, United States of America.
- Los Alamos National Laboratory, Center Alamos for Integrated Nanotechnologies, Los Alamos, NM, United States of America.
- Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, United States of America.
ORCID-Profile: Nileena Velappan, Daniel Bedinger, Austin J Watt, Rebecca J Abergel, Antonietta M Lillo
Förderung
- Los Alamos National Laboratory
Zitieren
APA
Velappan, N., Biryukov, S. S., Rill, N. O., Klimko, C. P., Rosario-Acevedo, R., Shoe, J. L., Hunter, M., Dankmeyer, J. L., Fetterer, D. P., Bedinger, D., Phipps, M. E., Watt, A. J., Abergel, R. J., Dichosa, A., Kozimor, S. A., Cote, C. K., & Lillo, A. M. (2024). Characterization of two affinity matured Anti-Yersinia pestis F1 human antibodies with medical countermeasure potential. PLOS ONE. https://doi.org/10.1371/journal.pone.0305034
Vancouver
Velappan N, Biryukov SS, Rill NO, Klimko CP, Rosario-Acevedo R, Shoe JL, et al. Characterization of two affinity matured Anti-Yersinia pestis F1 human antibodies with medical countermeasure potential. PLOS ONE. 2024. doi:10.1371/journal.pone.0305034
BibTeX
@article{Velappan2024,
author = {Velappan, Nileena and Biryukov, Sergei S and Rill, Nathaniel O and Klimko, Christopher P and Rosario-Acevedo, Raysa and Shoe, Jennifer L and Hunter, Melissa and Dankmeyer, Jennifer L and Fetterer, David P and Bedinger, Daniel and Phipps, Mary E and Watt, Austin J and Abergel, Rebecca J and Dichosa, Armand and Kozimor, Stosh A and Cote, Christopher K and Lillo, Antonietta M},
title = {Characterization of two affinity matured Anti-Yersinia pestis F1 human antibodies with medical countermeasure potential},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0305034}
}
EUVIMED